Tumor location Prior lines Next best treatment: clinician-defined Next best treatment: MP-defined Clinical observations Biomarkers with/without benefit Chemotherapy versus biological/targeted therapy PFS ratio Cervical 2 Irinotecan + 5-FU (FOLFIRI started) CB 5/5 7 versus 2 1.91 Gall bladder 3 FOLFIRI CB 3/5 5 versus 0 2.40 Skin (Merckel) 3 Epirubicin + cisplatin + 5-FU P 4/5 8 versus 0 1.50 Colorectal 3 Mitoxantrone/5-FU Epirubicin + cisplatin + 5-FU P 4/5 8 versus 0 0.28 Cervical 2 Nil FOLFIRI CB 15/4 10 versus 7 1.43 Pancreas (adenocarcinoma) 2 Nil Epirubicin + cisplatin + 5-FU then trastuzumab (?)/erlotinib CB 7/2 7 versus 6 1.33 Gastric 2 FOLFIRI Gemcitabine + oxaliplatin CB 15/5 12 versus 3 1.76 Leiomyosarcoma 2 Trabectedin Sunitinib CB 11/6 9 versus 7 14.87 Breast (ER− /HER2+ ) 3 Trastuzumab/capecitabine then liposomal doxorubicin then trastuzumab/irinotecan Trastuzumab + irinotecan CB 15/9 20 versus 3 0.67 Uterus 2 Doxorubicin + cyclophosphamide P 6/16 8 versus 0 0.28 Breast 2 Nab-paclitaxel (intolerant), cyclophosphamide + methotrexate + 5-FU P 8/11 17 versus 0 NA Small bowel 2 Died before assessment P 6/16 7 versus 0 NA Esophageal 2 FOLFIRI P 7/16 7 versus 2 NA Lung 2 Cisplatin + pemetrexed CB 14/12 7 versus 3 0.59 Malignant mesothelioma 2 Cisplatin + pemetrexed Cisplatin + nab-paclitaxel + doxorubicin P 5/19 4 versus 0 NA Ovarian 3 Nab-paclitaxel Topotecan (also anthracyclines/nab-paclitaxel/hormones) CB 8/15 12 versus 0 1.00 Cholangiocarcinoma 2 Epirubicin + cisplatin + 5-FU Cisplatin + gemcitabine CB 5/13 7 versus 0 NA Mesothelioma 2 Nil FOLFIRI P 2/16 5 versus 0 0.70 Gastrointestinal 2 FOLFIRI FOLFIRI P 4/18 5 versus 0 0.77 Colon (adenocarcinoma) 2 Mitomycin-C + 5-FU Carboplatin + gemcitabine CB 13/8 10 versus 2 1.50 Cervical 2 Irinotecan + 5-FU (FOLFIRI started) CB 5/5 7 versus 2 2.00 Ovarian (serous adenocarcinoma) 2 Cisplatin + liposomal doxorubicin Carboplatin + liposomal doxorubicin CB 9/9 14 versus 0 3.80 Lung (adenocarcinoma) 3 Vinorelbine Nab-paclitaxel P 10/11 9 versus 0 NA Pleura (adenocarcinoma) 3 FOLFIRI CB 9/6 11 versus 0 2.80 Prostate 3 Mitoxantrone Irinotecan + 5-FU CB 12/5 16 versus 0 1.83 Ovarian (serous adenocarcinoma) 2 Cisplatin + liposomal doxorubicin Cisplatin + liposomal doxorubicin CB 9/4 10 versus 0 3.00 Ovarian (serous adenocarcinoma) 2 Cisplatin + liposomal doxorubicin Doxorubicin P 6/8 7 versus 2 0.50 Colon (adenocarcinoma) 2 Gemcitabine + nab-paclitaxel P 8/9 8 versus 0 0.87 Mesothelioma 2 Vinorelbine Gemcitabine + nab-paclitaxel CB 8/7 7 versus 0 0.30 Gastric (adenocarcinoma) 2 Etoposide + leucovorin + 5-FU FOLFIRI CB 10/6 11 versus 3 2.85 Ductal breast carcinoma 1 Nab-paclitaxel CB 10/3 16 versus 3 NA Totals CB = 19; = 12 253/279 291 versus 45
